EUCTR2008-006786-92-GB进行中（未招募）不适用
Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Males and females aged 18 to 55 years (inclusive).
- •2. Women of childbearing potential must:
- •Have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline.
- •Agree to use two methods of contraception from the screening visit until 8 weeks after study drug discontinuation.
- •– Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository, or
- •– Oral, implantable, transdermal or injectable hormonal contraceptives in combination with one barrier method, i.e., condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ suppository.
- •Abstention and rhythm methods are not acceptable methods of contraception.
- •3. Presenting with a diagnosis of RRMS as defined by the revised (2005) McDonald Diagnostic Criteria for Multiple Sclerosis (MS).
- •4. Ambulatory and with an Expanded Disability Status Scale (EDSS) score between 0 and 5.5 (inclusive).
- •5. With at least one of the following characteristics of RRMS:
- •One or more documented relapse(s) within 12 months prior to the screening visit,
- •Two or more documented relapses within 24 months prior to the screening visit,
- •At least one gadolinium-enhancing lesion detected on T1-weighted MRI at the Screening visit (based on central reading).
- •6. In a stable clinical condition:
- •Without a clinical exacerbation of MS for at least 30 days prior to randomization (exacerbation of MS is defined as one or more new symptom(s), or worsening of existing symptoms, not associated with fever or infection, and lasting for at least 24 hours).
- •7. Signed informed consent prior to initiation of any study mandated procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Breast feeding women.
- •2. A diagnosis of MS categorized as primary progressive or secondary progressive or progressive relapsing.
- •3. Treatment with
- •Within 30 days prior to randomization:
- •Systemic corticosteroids or adrenocorticotropic hormone (ACTH)
- •Treatment with ß-blockers, diltiazem, verapamil, or digoxin or QT-prolonging drugs (as listed in Appendix 9), for any indication
- •Within 3 months prior to randomization:
- •Interferon or glatiramer acetate
- •Systemic immunosuppressive treatment (e.g., cyclosporine, sirolimus, mycophenolic acid)
- •Vaccination with live vaccines
- •Plasma exchange (plasmapheresis, cytapheresis)
- •Treatment with an investigational drug (within 3 months or 5 half-lives of the drug, whichever is longer), except biological agents (see below)
- •Within 6 months prior to randomization:
- •Azathioprine or methotrexate
- •Natalizumab (or previous failure to natalizumab)
- •Intravenous immunoglobulin
- •Non-lymphocyte-depleting biologic agents (e.g., daclizumab)
- •At any time prior to randomization:
- •Cyclophosphamide, mitoxantrone, or cladribine
- •Lymphocyte-depleting biologic agents such as alemtuzumab or rituximab
- •4. Patient currently treated for an autoimmune disorder other than MS.
- •5. Contraindications for MRI such as:
- •Pacemaker, any metallic implants such as artificial heart valves, aneurysm/vessel clips and any metallic material in high-risk areas
- •Known allergy to any gadolinium contrast agent
- •Severe renal insufficiency defined as a creatinine clearance < 30 mL/min according to the Cockroft-Gault formula
- •Claustrophobia
- •6. Ongoing bacterial, viral or fungal infection (with the exception of onychomycosis and dermatomycosis), positive hepatitis B surface antigen or hepatitis C antibody tests.
- •7. Congenital or acquired severe immunodeficiency or known human immunodeficiency virus (HIV) infection.
- •8. Negative antibody test for varicella-zoster virus at screening.
- •9. History or presence of malignancy (except for surgically excised basal or squamous cell skin lesions), lymphoproliferative disease, or history of total lymphoid irradiation or bone marrow transplantation.
- •10. Poorly controlled type I or type II diabetes.
- •11. Macular edema or diabetic retinopathy (as confirmed within 30 days prior to randomization).
- •12. History of clinically significant drug or alcohol abuse.
- •13. Any of the following cardiovascular conditions:
- •Resting heart rate (HR) < 55 bpm, as measured by the pre-randomization ECG on Visit 3 (Day 1).
- •History or presence of ischemic heart disease.
- •History of or current valvular heart disease.
- •History of or current heart failure
- •History or presence of rhythm disorders (e.g., sino atrial heart block, sick sinus syndrome, second or third-degree atrioventricular (AV) block, ventricular arrhythmias, symptomatic bradycardia, atrial flutter or atrial fibrillation) or ongoing anti-arrhythmic therapy.
- •QTc > 470 msec (females) and QTc > 450 msec (males) in any of the ECGs performed at Screening, Baseline, or Day 1 prior to randomization.
- •History of syncope.
- •Uncontrolled arterial hypertension.
- •14. Any of the following pulmonary conditions:
- •Moderate or severe bronchial asthma or chronic obstructive pulmonary disease (COPD) stage II–IV, i.e., forced expiratory volume in 1 second (FEV1) < 70% of forced vital capacity (FVC), i.e., FEV1/FVC ratio < 0.7.
- •History of pulmonary fibrosis (scarring of the lung), pulmonary Langerhans’cell histiocytosis.
- •History of tuberculosis, chest X-ray findin
研究者
相似试验
进行中（未招募）
不适用
Multicenter, randomized, double-blind, placebo-controlled, study to evaluate the effect of ITF2357 on mucosal healing in patients with moderate-to-severe active Crohn?s Disease - DSC/06/2357/23Crohn's diseaseMedDRA version: 9.1Level: LLTClassification code 10011401Term: Crohn's diseaseEUCTR2007-000189-19-ITITALFARMACO80
尚未招募
Unknown
Multicenter, randomized, double-blind, placebo-controlled study toassess the effects of enavogliflozin on outcomes in patients withfunctional tricuspid regurgitation and preserved left ventricularejection fractioDiseases of the circulatory systemKCT0008631Asan Medical Center588
进行中（未招募）
不适用
Multicenter, randomized, double-blind, placebo-controlled parallel group study to demonstrate the efficacy (quality of life) and safety of the standardized mistletoe extract PS76A2 during chemotherapy and follow-up in patients with breast cancerFemale patients with breast cancer shortly after surgery [pTNM classification: pT1-T4, pN0-N+ (0-9 positive lymph nodes), pM0] qualified for adjuvant chemotherapy according to FEC scheme as standard of careMedDRA version: 13.1Level: PTClassification code 10057654Term: Breast cancer femaleSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-000841-36-PLRottapharm Madaus, Madaus GmbH320
进行中（未招募）
不适用
Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosisrelapsing-remitting multiple scelorsisMedDRA version: 9.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2008-006786-92-HUActelion Pharmaceuticals Ltd400
进行中（未招募）
1 期
Multicenter, randomized, double-blind, placebo-controlled, Phase IIa study to evaluate the efficacy, safety, and tolerability of ACT-128800, an S1P1 receptor agonist, administered for 6 weeks to subjects with moderate to severe chronic plaque psoriasisEUCTR2008-001443-19-FRActelion Pharmaceuticals Ltd60